Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81434-retinal-disorders-multi-gene-genomic-panel
    Ask Trek AI about this page

    CPT 81434: Retinal Disorders Genomic Sequence Analysis Panel

    Commercial payers pay $559 on average nationally for this procedure.

    CPT code 81434 describes a laboratory-performed genomic sequence analysis panel that evaluates a patient specimen for genetic variants across a set of at least 15 genes associated with retinal disorders, representing clinical molecular diagnostic testing typically performed as a multigene next-generation sequencing panel; the service type is genetic testing / genomic sequence analysis and the typical site of service is a clinical diagnostic laboratory or reference molecular genetics laboratory where specimens are processed and sequenced.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81434 policy alerts

    Get alerted when payer policies referencing 81434 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    Commercial rates for CPT 81434 center around BUCA’s mean of $558.80 as a proxy for average commercial reimbursement; several large national payers trade around that level but with meaningful spread. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $713.40, and Cigna’s IQR is $511.20, both notably wider than BUCA’s IQR of $344.10. Aetna and UnitedHealth Group show tighter mid‑range dispersion: Aetna’s IQR is $238.10 and UnitedHealth Group’s IQR is $346.80, indicating more consistency near their medians. Comparing extremes, Blue Cross Blue Shield exhibits the widest interquartile dispersion, suggesting greater variability in contracted commercial rates, while Aetna is the tightest among the payers listed. Published median and mean differences also reflect that Cigna and Blue Cross Blue Shield push higher upper quartiles, whereas Aetna and UnitedHealth Group cluster more closely around middle values.

    National Payer Mean Reimbursement Rates

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 34-year-old female with a personal history of early-onset breast cancer and a strong family history of breast and ovarian cancer is referred to a medical genetics clinic for comprehensive hereditary cancer testing. The clinician orders a multi-gene genomic sequencing panel focused on retinal disorder genes listed under 81434 because the patient has concurrent unexplained retinal dystrophy symptoms and a complex family history that may include syndromic associations affecting both ocular and breast/ovarian risk. A peripheral blood specimen is collected in the outpatient clinic and sent to a CLIA-certified molecular diagnostics laboratory. The laboratory performs next-generation sequencing (NGS) covering at least the 15 retinal disorder-related genes specified by the 81434 descriptor, including sequence variant detection and reporting of pathogenic, likely pathogenic, and variants of uncertain significance. The report is reviewed by a board-certified clinical molecular geneticist or genetic counselor, who provides interpretation and documents implications for patient management and family testing.

    Typical workflow steps:

    • Referral and pretest genetic counseling in outpatient genetics or ophthalmology clinic

    • Collection of specimen (blood) in the clinic and shipment to reference molecular laboratory

    • Laboratory performs genomic sequence analysis panel for retinal disorder genes per 81434

    • Laboratory quality control, variant interpretation, and generation of clinical report

    • Results returned to ordering provider; post-test counseling and coordination of cascade testing as indicated

    Typical site of service: outpatient clinic or ambulatory surgical center for specimen collection and reference molecular laboratory for analysis.

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207SG0201X
    207SC0300X
    207SG0202X
    207SG0203X
    207SG0205X
    276400000X
    2086S0102X
    103TM1800X

    Related ICD-10-CM Codes

    20 rows

    ICD-10-CM CodeDescription
    C50.919Malignant neoplasm of unspecified site of unspecified female breast
    E70.0Classical phenylketonuria
    E83.39Other disorders of phosphorus metabolism
    E88.09Other disorders of plasma-protein metabolism, not elsewhere classified
    G71.3Mitochondrial myopathy, not elsewhere classified
    H26.9Unspecified cataract
    H31.9Unspecified disorder of choroid
    H35.50Unspecified hereditary retinal dystrophy
    H35.52Pigmentary retinal dystrophy
    H35.53Other dystrophies primarily involving the sensory retina

    Showing 1–10 of 20

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Typical patient scenario: symptomatic patient with retinal dystrophy plus family history of hereditary cancer or carrier status concerns, or a patient undergoing broader genetic assessment where retinal gene panel is indicated alongside hereditary cancer gene testing.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81211BRCA1 and BRCA2 analysis; targeted sequence analysisMay be ordered alongside 81434 when hereditary breast/ovarian cancer risk assessment is required in the same patient
    81213BRCA1 and BRCA2 analysis; full gene sequenceAlternative or complementary hereditary cancer testing when full sequencing of BRCA genes is indicated in the clinical workup
    81432Hereditary breast cancer-related disorders, genomic sequence analysis panelClinically related panel frequently ordered in parallel with retinal or syndromic panels when there is overlap in family cancer history
    81433Hereditary breast cancer-related disorders, duplication/deletion analysis panelPerformed when copy number variants in BRCA1/BRCA2 are suspected in addition to sequencing panels like 81434
    81435Hereditary colon cancer disorders, genomic sequence analysis panelAnother hereditary cancer panel that may be part of a broader genomic evaluation when multiple cancer predisposition syndromes are considered